DMAC (DiaMedica Therapeutics) Short-Term Debt: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.69
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Short-Term Debt?

DiaMedica Therapeutics DMAC -0.89% 31 Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

DiaMedica Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.00 Mil.

DiaMedica Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

DiaMedica Therapeutics Short-Term Debt Related Terms

DiaMedica Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Short-Term Debt Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DiaMedica Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
DiaMedica Therapeutics (DMAC) has a Short-Term Debt of $0.00 Mil as of Jun. 2026.
Is DiaMedica Therapeutics' Short-Term Debt too high?
DiaMedica Therapeutics' current Short-Term Debt is $0.00 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Short-Term Debt compare to XFOR and IKT?
DiaMedica Therapeutics' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. DiaMedica Therapeutics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price